Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lisa Grüntkemeier"'
Autor:
Vera Rebmann, Esther Schwich, Rafael Tomoya Michita, Lisa Grüntkemeier, Ann-Kathrin Bittner, Hana Rohn, Peter A. Horn, Oliver Hoffmann, Rainer Kimmig, Sabine Kasimir-Bauer
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
Despite major improvements in diagnostics and therapy in early as well as in locally advanced breast cancer (LABC), metastatic relapse occurs in about 20% of patients, often explained by early micro-metastatic spread into bone marrow by disseminated
Externí odkaz:
https://doaj.org/article/dbdf2d891d02448388189ee667f8d62f
Autor:
Susana Garcia de Arriba, Lisa Grüntkemeier, Manuel Häuser, Theodor W. May, Clarissa Masur, Petra Stute
Publikováno v:
PLoS ONE, Vol 17, Iss 5 (2022)
This prospective, open-label, multicentre, multinational, randomised trial investigated the non-inferiority of treatment with a vaginal hormone-free moisturising cream compared to a vaginal estriol (0.1%) cream in a panel of post-menopausal women suf
Externí odkaz:
https://doaj.org/article/1d6f951b29b748e3b1bcdf5bbe3755bc
Autor:
Vera, Rebmann, Esther, Schwich, Rafael Tomoya, Michita, Lisa, Grüntkemeier, Ann-Kathrin, Bittner, Hana, Rohn, Peter A, Horn, Oliver, Hoffmann, Rainer, Kimmig, Sabine, Kasimir-Bauer
Publikováno v:
Frontiers in Immunology
Despite major improvements in diagnostics and therapy in early as well as in locally advanced breast cancer (LABC), metastatic relapse occurs in about 20% of patients, often explained by early micro-metastatic spread into bone marrow by disseminated
Autor:
Lisa Grüntkemeier, Aditi Khurana, Farideh Zamaniyan Bischoff, Oliver Hoffmann, Rainer Kimmig, Mathew Moore, Philip Cotter, Sabine Kasimir-Bauer
Background In breast cancer (BC), overexpression of HER2 on the primary tumor (PT) is determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to stratify samples as negative, equivocal and positive to identify patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bed0bc42dd13302353801d44e26e877
https://doi.org/10.21203/rs.3.rs-820771/v1
https://doi.org/10.21203/rs.3.rs-820771/v1
Autor:
Farideh Z. Bischoff, Lisa Grüntkemeier, Philip D. Cotter, Mathew W. Moore, S Kasimir-Bauer, R Kimmig, Aditi Khurana, Oliver Hoffmann
Publikováno v:
Cancer Research. 78:4530-4530
Background: In breast cancer (BC), HER2 expression does not only differ within various primary tumor (PT) areas, but also with respect to the expression on circulating tumor cells (CTCs). Despite clinical guidelines defined by CAP/ASCO, PT HER2 analy